Celiac disease is an immune-mediated enteropathy triggered by gluten in genetically predisposed individuals (HLA-DQ2/DQ8), with a global seroprevalence of approximately 1.4%. However, only one in four ...
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...
No signs of graft rejection or de novo donor-specific HLA antibodies - Tegoprubart continues to demonstrate a favorable safety and tolerability profile IRVINE, Calif, March 16, 2026 (GLOBE NEWSWIRE) - ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced today that its proprietary first-in-class trispecific antibody, ...
When a patient undergoes an organ transplant, failure to match the donor and recipient can lead to the recipient's immune system attacking the new organ, a process triggered by a specific HLA (human ...
The final, formatted version of the article will be published soon. Donor-specific HLA antibodies (DSAs) are well-established mediators of antibody-mediated rejection (AMR), but growing evidence ...
ABSTRACT: In hypersensitized patients, Kidney Transplant (KT) rates are low due to the risk of organ loss due to rejection. Desensitization (DS) protocols have been developed to prevent rejection, ...
Overall, evidence suggests that outcomes arising from HLA-matched and HLA-mismatched donors are similar when the same GVHD prophylaxis is used. A less stringent approach to allogeneic hematopoietic ...
In a trial, 8 of 14 highly sensitized patients receiving a novel treatment combination received a kidney transplant from previously incompatible donors. Treatment with daratumumab and belatacept ...
The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results